Hacer Bozdemir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hacer Bozdemir has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Kezban Aslan-Kara
Department of Neurology, Faculty of Medicine, Çukurova University, Adana, Turkiye
4 shared publications - Mehmet Taylan Peköz
Department of Neurology, Faculty of Medicine, Çukurova University, Adana, Turkiye
4 shared publications - Mehmet Balal
Çukurova University, Faculty of Medicine, Department of Neurology, Adana, Türkiye
2 shared publications - Turgay Demir
Department of Neurology, Faculty of Medicine, Çukurova University, Adana, Turkiye
2 shared publications - Alevtina Ersoy
Department of Neurology, Erzincan Binali Yıldırım University, Faculty of Medicine, Erzincan, Türkiye
1 shared publication - Ali Akyol
Department of Neurology Adnan Menderes University School of Medicine Aydın Türkiye
1 shared publication
Latest Publications
Birth outcomes in pregnant women with epilepsy: A Nationwide multicenter study from Türkiye
Objective: The present study was aimed at investigating the effects of anti‐seizure medications (ASMs), patient demographic characteristics, and the seizure type and frequency on the development of congenital malformations (CMs) in the infants of pregnant women with epilepsy (PWWE).Methods: PWWE followed up at the neurology outpatient clinic of 21 centers between 2014 and 2019 were included in this prospective study. The follow‐up of PWWE was conducted using structured, general pregnant follow‐up forms prepared by the Pregnancy and Epilepsy Study Committee. The newborns were examined by a neonatologist after delivery and at 1 and 3 months postpartum.Results: Of the infants of 759 PWWE, 7.2% had CMs, with 5.6% having major CMs. Polytherapy, monotherapy, and no medications were received by 168 (22.1%), 548 (72.2 %), and 43 (5.7 %) patients, respectively. CMs were detected at an incidence of 2.3% in infants of PWWE who did not receive medication, 5.7% in infants of PWWE who received monotherapy, and 13.7% in infants of PWWE who received polytherapy. The risk of malformation was 2.31‐fold (95% confidence interval (CI): 1.48–4.61, p < .001) higher in infants of PWWE who received polytherapy. Levetiracetam was the most frequently used seizure medication as monotherapy, with the highest incidence of CMs occurring with valproic acid (VPA) use (8.5%) and the lowest with lamotrigine use (2.1%). The incidence of CMs was 5% at a carbamazepine dose p = .041) in infants of PWWE receiving high‐dose ASMs.Significance: Birth outcomes of PWWE receiving and not receiving ASMs were evaluated. The risk of CMs occurrence was higher, particularly in infants of PWWE using VPA and receiving polytherapy. The incidence of CMs was found to be lower in infants of PWWE receiving lamotrigine.
Birth outcomes in pregnant women with epilepsy: A Nationwide multicenter study from Türkiye
Objective: The present study was aimed at investigating the effects of anti‐seizure medications (ASMs), patient demographic characteristics, and the seizure type and frequency on the development of congenital malformations (CMs) in the infants of pregnant women with epilepsy (PWWE).Methods: PWWE followed up at the neurology outpatient clinic of 21 centers between 2014 and 2019 were included in this prospective study. The follow‐up of PWWE was conducted using structured, general pregnant follow‐up forms prepared by the Pregnancy and Epilepsy Study Committee. The newborns were examined by a neonatologist after delivery and at 1 and 3 months postpartum.Results: Of the infants of 759 PWWE, 7.2% had CMs, with 5.6% having major CMs. Polytherapy, monotherapy, and no medications were received by 168 (22.1%), 548 (72.2 %), and 43 (5.7 %) patients, respectively. CMs were detected at an incidence of 2.3% in infants of PWWE who did not receive medication, 5.7% in infants of PWWE who received monotherapy, and 13.7% in infants of PWWE who received polytherapy. The risk of malformation was 2.31‐fold (95% confidence interval (CI): 1.48–4.61, p < .001) higher in infants of PWWE who received polytherapy. Levetiracetam was the most frequently used seizure medication as monotherapy, with the highest incidence of CMs occurring with valproic acid (VPA) use (8.5%) and the lowest with lamotrigine use (2.1%). The incidence of CMs was 5% at a carbamazepine dose p = .041) in infants of PWWE receiving high‐dose ASMs.Significance: Birth outcomes of PWWE receiving and not receiving ASMs were evaluated. The risk of CMs occurrence was higher, particularly in infants of PWWE using VPA and receiving polytherapy. The incidence of CMs was found to be lower in infants of PWWE receiving lamotrigine.
- Open Access
- 1 November 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (11) , 1112-1118
Frequency and economic burden of psychogenic non-epileptic seizures in patients applying for disability benefits due to epilepsy
Background Psychogenic non-epileptic seizures (PNES) resemble epileptic seizures and are often misdiagnosed as epilepsy. Objective To investigate the frequency of PNES and to calculate the economic burden of the patients who admitted to video-electroencephalographicmonitoring (VEM) to obtain a diagnosis of epilepsy in order to apply for disability retirement. Methods The present retrospective study included 134 patients who required disability reports between 2013 and 2019 and had their definite diagnoses after VEM. Following VEM, the patients were divided into three groups: epilepsy, PNES, and epilepsy + PNES. Results In total, 22.4% (n = 30) of the patients were diagnosed with PNES, 21.6% (n = 29) with PNES and epilepsy, and 56% (n = 75), with epilepsy. The frequency of PNES among all patients was of 44% (n = 59). In patients with PNES alone, the annual cost of using anti-seizure medication was of 160.67 ± 94.04 dollars; for psychostimulant drugs, it was of 148.3 ± 72.48 dollars a year; and the mean direct cost for diagnostic procedures was of 582.9 ± 330.0 (range: 103.52–1601.3) dollars. Conclusions Although it is challenging to determine the qualitative and quantitative total cost in these patient groups, early diagnosis and sociopsychological support will reduce the additional financial burden on the health system and increase the quality of life of the patients. Antecedentes As crises psicogênicas não epilépticas (CPNE) se assemelham a crises epilépticas, e muitas vezes são diagnosticadas erroneamente como epilepsia. Objetivo Investigar a frequência de CPNE e calcular o impacto econômico dos pacientes internados para serem submetidos a monitoramento videoencefalográfico (MVE) para obter um diagnóstico de epilepsia e requerer aposentadoria por invalidez. Métodos Este estudo retrospectivo incluiu 134 pacientes que solicitaram laudo médico de incapacidade entre 2013 e 2019, e obtiveram seus diagnósticos definitivos após serem submetidos a MEV. Os pacientes foram divididos em três grupos: epilepsia, CPNE, e epilepsia + CPNE. Resultados Após o MEV, 22,4% (n = 30) dos pacientes foram diagnosticados com CPNE, 21,6% (n = 29), com CPNE + epilepsia, e 56%, com epilepsia. A frequência de CPNE entre todos os pacientes foi de 44% (n = 59). Em pacientes somente com CPNE, o custo anual do uso de anticonvulsivantes foi de US$ 160,67 ± 94,04; para os psicoestimulantes, o custo anual foi de US$ 148,3 ± 72,48; e a média do custo direto de procedimentos diagnósticos foi de US$ 582,9 ± 330,0 (variação: 103,52–1601,3). Conclusões Embora seja um desafio determinar o custo total qualitativo e quantitativo nesses grupos de pacientes, o diagnóstico precoce e o apoio sociopsicológico reduzirão o impacto financeiro adicional ao sistema de saúde e aumentarão a qualidade de vida dos pacientes. Received: 01 December 2021 Accepted: 29 May 2022 Article published online: 28 December 2022 © 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 1 November 2022
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 80 (11) , 1112-1118
Open AccessFrequency and economic burden of psychogenic non-epileptic seizures in patients applying for disability benefits due to epilepsy
Background Psychogenic non-epileptic seizures (PNES) resemble epileptic seizures and are often misdiagnosed as epilepsy. Objective To investigate the frequency of PNES and to calculate the economic burden of the patients who admitted to video-electroencephalographicmonitoring (VEM) to obtain a diagnosis of epilepsy in order to apply for disability retirement. Methods The present retrospective study included 134 patients who required disability reports between 2013 and 2019 and had their definite diagnoses after VEM. Following VEM, the patients were divided into three groups: epilepsy, PNES, and epilepsy + PNES. Results In total, 22.4% (n = 30) of the patients were diagnosed with PNES, 21.6% (n = 29) with PNES and epilepsy, and 56% (n = 75), with epilepsy. The frequency of PNES among all patients was of 44% (n = 59). In patients with PNES alone, the annual cost of using anti-seizure medication was of 160.67 ± 94.04 dollars; for psychostimulant drugs, it was of 148.3 ± 72.48 dollars a year; and the mean direct cost for diagnostic procedures was of 582.9 ± 330.0 (range: 103.52–1601.3) dollars. Conclusions Although it is challenging to determine the qualitative and quantitative total cost in these patient groups, early diagnosis and sociopsychological support will reduce the additional financial burden on the health system and increase the quality of life of the patients. Antecedentes As crises psicogênicas não epilépticas (CPNE) se assemelham a crises epilépticas, e muitas vezes são diagnosticadas erroneamente como epilepsia. Objetivo Investigar a frequência de CPNE e calcular o impacto econômico dos pacientes internados para serem submetidos a monitoramento videoencefalográfico (MVE) para obter um diagnóstico de epilepsia e requerer aposentadoria por invalidez. Métodos Este estudo retrospectivo incluiu 134 pacientes que solicitaram laudo médico de incapacidade entre 2013 e 2019, e obtiveram seus diagnósticos definitivos após serem submetidos a MEV. Os pacientes foram divididos em três grupos: epilepsia, CPNE, e epilepsia + CPNE. Resultados Após o MEV, 22,4% (n = 30) dos pacientes foram diagnosticados com CPNE, 21,6% (n = 29), com CPNE + epilepsia, e 56%, com epilepsia. A frequência de CPNE entre todos os pacientes foi de 44% (n = 59). Em pacientes somente com CPNE, o custo anual do uso de anticonvulsivantes foi de US$ 160,67 ± 94,04; para os psicoestimulantes, o custo anual foi de US$ 148,3 ± 72,48; e a média do custo direto de procedimentos diagnósticos foi de US$ 582,9 ± 330,0 (variação: 103,52–1601,3). Conclusões Embora seja um desafio determinar o custo total qualitativo e quantitativo nesses grupos de pacientes, o diagnóstico precoce e o apoio sociopsicológico reduzirão o impacto financeiro adicional ao sistema de saúde e aumentarão a qualidade de vida dos pacientes. Received: 01 December 2021 Accepted: 29 May 2022 Article published online: 28 December 2022 © 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
- 20 September 2020
- Published by Turkish Journal of Family Medicine and Primary Care in Turkish Journal of Family Medicine and Primary Care
- Vol. 14 (3) , 407-413
Creutzfeldt-Jacob Disease, As a Rare Cause of Dementia Should Not be Forgotten: Single-Center Experience
Introduction: Dementia, which is an important public health problem, is divided into two groups as primary and secondary dementia. Creutzfeldt–Jakob disease (CJD), which is rarely seen, is a secondary cause of dementia with a rapidly progressive course. It is a fatal neurodegenerative disorder of infectious spongiform encephalopathy that can affect humans and animals. Sporadic CJD is the most common type that can present in four forms and has typical clinical presentations of progressive cognitive impairment, myoclonus, and ataxia. We aimed to discuss the demographic, clinical, and laboratory findings of CJD cases diagnosed in the neurointensive care unit. Methods: Sixteen patients were included in this retrospective study. Age, sex, complaints on admission, duration from symptom onset to mortality, neurologic examination, brain magnetic resonance imaging (MRI), electroencephalography (EEG), and the protein 14.3.3 status of the cerebrospinal fluid (CSF) were recorded. Results: The mean age was 61.18 ± 9.1 years (range, 37–73 years), and the most common complaints on admission were cognitive impairment, disturbance in consciousness, ataxia, and gait disturbance. CSF protein 14-3-3 was positive in 100% of patients. The most common findings were periodic sharp and wave complexes on EEG, cortical or putamen and caudate nucleus hyperintensity, cortical and cerebellar atrophy on MRI. One of the patients was diagnosed as variant CJD, and the others were diagnosed as the sporadic form. Conclusions: CJD should be kept in mind in patients with myoclonus or ataxia accompanied by progressive cognitive impairment. Neuroimaging, serial EEG recordings, CSF analysis, and histopathologic examination should be performed for diagnosis.
- 20 September 2020
- Published by Turkish Journal of Family Medicine and Primary Care in Turkish Journal of Family Medicine and Primary Care
- Vol. 14 (3) , 407-413
Creutzfeldt-Jacob Disease, As a Rare Cause of Dementia Should Not be Forgotten: Single-Center Experience
Introduction: Dementia, which is an important public health problem, is divided into two groups as primary and secondary dementia. Creutzfeldt–Jakob disease (CJD), which is rarely seen, is a secondary cause of dementia with a rapidly progressive course. It is a fatal neurodegenerative disorder of infectious spongiform encephalopathy that can affect humans and animals. Sporadic CJD is the most common type that can present in four forms and has typical clinical presentations of progressive cognitive impairment, myoclonus, and ataxia. We aimed to discuss the demographic, clinical, and laboratory findings of CJD cases diagnosed in the neurointensive care unit. Methods: Sixteen patients were included in this retrospective study. Age, sex, complaints on admission, duration from symptom onset to mortality, neurologic examination, brain magnetic resonance imaging (MRI), electroencephalography (EEG), and the protein 14.3.3 status of the cerebrospinal fluid (CSF) were recorded. Results: The mean age was 61.18 ± 9.1 years (range, 37–73 years), and the most common complaints on admission were cognitive impairment, disturbance in consciousness, ataxia, and gait disturbance. CSF protein 14-3-3 was positive in 100% of patients. The most common findings were periodic sharp and wave complexes on EEG, cortical or putamen and caudate nucleus hyperintensity, cortical and cerebellar atrophy on MRI. One of the patients was diagnosed as variant CJD, and the others were diagnosed as the sporadic form. Conclusions: CJD should be kept in mind in patients with myoclonus or ataxia accompanied by progressive cognitive impairment. Neuroimaging, serial EEG recordings, CSF analysis, and histopathologic examination should be performed for diagnosis.
- 1 March 2019
- Published by Galenos Yayinevi in Journal of Turkish Sleep Medicine
- Vol. 6 (1) , 10-15
Chronic Intermittent Hypoxemia in Patients with Obstuctive Sleep Apnea Syndrome Causes Reduction of Peripheral Nerve Motor Fibers (Unit Number)
- 1 March 2019
- Published by Galenos Yayinevi in Journal of Turkish Sleep Medicine
- Vol. 6 (1) , 10-15
Chronic Intermittent Hypoxemia in Patients with Obstuctive Sleep Apnea Syndrome Causes Reduction of Peripheral Nerve Motor Fibers (Unit Number)
- 19 July 2010
- Published by Taylor & Francis in Neurological Research
- Vol. 32 (6) , 620-624
The effect of electrophysiological and neuroimaging findings on the prognosis of juvenile myoclonic epilepsy proband
Juvenile myoclonic epilepsy (JME) is a well-defined idiopathic generalized epileptic syndrome, and diagnostic criteria for JME are to have a normal brain imaging and clinical evidence of typical epileptic seizures. The aim of this study is to evaluate electrophysiological and neuroimaging findings of JME and determine their relationship with prognosis. Thirty-two patients (23 women and nine men) with a mean age of 22 (16-37) years were included in this study. Interictal electroencephalography (EEG), magnetic resonance imaging (MRI) and single photon emission computed tomography (SPECT) were carried out in all patients. Analysis of premedication EEGs revealed primary generalized pattern activity in 75% (n=24) and focal abnormalities in 18.75% (n=6). MRI was abnormal in seven (21.88%) patients (two with arachnoid cyst, two with mild cerebral atrophy, two with ventricular enlargement and one with single gliotic lesion), and SPECT imaging detected hypoperfusion in 15 (47%) patients. Hypoperfusion was mostly found on the parietal lobe. We found that, after medication, only 6.25% of EEGs had primary generalized pattern activity (p<0.0001); nevertheless, the prognosis was good in patients who had typical EEG findings (p=0.106). The prognosis of patients with MRI abnormalities was grave (p=0.023). Twenty percent of the patients who had SPECT abnormalities were seizure free, and 80% of them had been partially controlled (p=0.059). There were no correlations between MRI abnormalities, EEG and SPECT findings.
- 19 July 2010
- Published by Taylor & Francis in Neurological Research
- Vol. 32 (6) , 620-624
The effect of electrophysiological and neuroimaging findings on the prognosis of juvenile myoclonic epilepsy proband
Juvenile myoclonic epilepsy (JME) is a well-defined idiopathic generalized epileptic syndrome, and diagnostic criteria for JME are to have a normal brain imaging and clinical evidence of typical epileptic seizures. The aim of this study is to evaluate electrophysiological and neuroimaging findings of JME and determine their relationship with prognosis. Thirty-two patients (23 women and nine men) with a mean age of 22 (16-37) years were included in this study. Interictal electroencephalography (EEG), magnetic resonance imaging (MRI) and single photon emission computed tomography (SPECT) were carried out in all patients. Analysis of premedication EEGs revealed primary generalized pattern activity in 75% (n=24) and focal abnormalities in 18.75% (n=6). MRI was abnormal in seven (21.88%) patients (two with arachnoid cyst, two with mild cerebral atrophy, two with ventricular enlargement and one with single gliotic lesion), and SPECT imaging detected hypoperfusion in 15 (47%) patients. Hypoperfusion was mostly found on the parietal lobe. We found that, after medication, only 6.25% of EEGs had primary generalized pattern activity (p<0.0001); nevertheless, the prognosis was good in patients who had typical EEG findings (p=0.106). The prognosis of patients with MRI abnormalities was grave (p=0.023). Twenty percent of the patients who had SPECT abnormalities were seizure free, and 80% of them had been partially controlled (p=0.059). There were no correlations between MRI abnormalities, EEG and SPECT findings.
- 1 December 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 553 (1-3) , 129-134
The actions of lamotrigine and levetiracetam on the conduction properties of isolated rat sciatic nerve
- 1 December 2006
- Published by Elsevier in European Journal of Pharmacology
- Vol. 553 (1-3) , 129-134
The actions of lamotrigine and levetiracetam on the conduction properties of isolated rat sciatic nerve